Sai-Hong I Ou

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3240308/publications.pdf

Version: 2024-02-01

260 papers	33,373 citations	9756 73 h-index	3997 176 g-index
263 all docs	263 docs citations	263 times ranked	21800 citing authors

#	Article	IF	Citations
1	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. Journal of Thoracic Oncology, 2022, 17, 411-422.	0.5	70
2	EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States. JTO Clinical and Research Reports, 2022, 3, 100285.	0.6	7
3	NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis. Trends in Cancer, 2022, 8, 242-258.	3.8	24
4	Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. Journal of Thoracic Oncology, 2022, 17, 568-577.	0.5	7
5	Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis. Lung Cancer, 2022, 164, 52-55.	0.9	8
6	Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy. Journal of Thoracic Oncology, 2022, 17, 182-185.	0.5	5
7	Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy. Journal of Ophthalmic and Vision Research, 2022, 17, 130-134.	0.7	1
8	First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS^{G12C} Solid Tumors (KRYSTAL-1). Journal of Clinical Oncology, 2022, 40, 2530-2538.	0.8	130
9	ORIENT-31 as the Sakigake â€œCharging Samuraiâ€•Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the â€œMeiji Modernizationâ€•of Post-3G EGFR TKI Progression?. Lung Cancer: Targets and Therapy, 2022, Volume 13, 13-21.	1.3	2
10	Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Nonâ€“small Cell Lung Cancer in the Global Phase III ALEX Trial. Clinical Cancer Research, 2022, 28, 1800-1808.	3.2	26
11	Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements. Npj Precision Oncology, 2022, 6, 20.	2.3	7
12	Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2022, 23, 311-319.	1.1	7
13	Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib. Lung Cancer: Targets and Therapy, 2022, Volume 13, 23-31.	1.3	3
14	<scp>NTRK</scp> fusion positive colorectal cancer is a unique subset of <scp>CRC</scp> with high <scp>TMB</scp> and microsatellite instability. Cancer Medicine, 2022, 11, 2541-2549.	1.3	22
15	Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Nonâ€“Small-Cell Lung Cancer From the Phase III CROWN Study. Journal of Clinical Oncology, 2022, 40, 3593-3602.	0.8	43
16	Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. Lung Cancer, 2022, 169, 67-76.	0.9	10
17	Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes. Current Medical Research and Opinion, 2022, 38, 1341-1350.	0.9	12
18	Adagrasib in Nonâ€“Small-Cell Lung Cancer Harboring a KRAS^{G12C} Mutation. New England Journal of Medicine, 2022, 387, 120-131.	13.9	269

#	Article	IF	Citations
19	Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. Journal of Thoracic Oncology, 2021, 16, 259-268.	0.5	29
20	Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies. JTO Clinical and Research Reports, 2021, 2, 100108.	0.6	20
21	Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase InhibitorsÂFor Advanced EGFR+ NSCLC. Journal of Thoracic Oncology, 2021, 16, 740-763.	0.5	115
22	A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review. JTO Clinical and Research Reports, 2021, 2, 100116.	0.6	12
23	Identification of Novel CDH1-NRG2Î± and F11R-NRG2Î± Fusions in NSCLC Plus Additional Novel NRG2Î± Fusions in Other Solid Tumors by Whole Transcriptome Sequencing. JTO Clinical and Research Reports, 2021, 2, 100132.	0.6	7
24	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusionâ€“Positive Lung Cancer. Clinical Cancer Research, 2021, 27, 2899-2909.	3.2	62
25	Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC. Journal of Thoracic Oncology, 2021, 16, 532-536.	0.5	23
26	Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships. Journal of Thoracic Oncology, 2021, 16, 706-708.	0.5	0
27	ALTA-2: Phase IIÂstudy of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. Future Oncology, 2021, 17, 1709-1719.	1.1	10
28	Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.. Journal of Clinical Oncology, 2021, 39, 3003-3003.	0.8	37
29	Crizotinib in Patients With MET-Amplified NSCLC. Journal of Thoracic Oncology, 2021, 16, 1017-1029.	0.5	84
30	Acquired Resistance to KRAS^{G12C} Inhibition in Cancer. New England Journal of Medicine, 2021, 384, 2382-2393.	13.9	482
31	Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. Lung Cancer, 2021, 157, 147-155.	0.9	30
32	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. JTO Clinical and Research Reports, 2021, 2, 100187.	0.6	11
33	Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RETâ€“positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib. Journal of Thoracic Oncology, 2021, 16, e51-e54.	0.5	16
34	Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Lung Cancer, 2021, 158, 126-136.	0.9	53
35	Clinicopathologic Features and Response to Therapy ofNRG1Fusionâ€“Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of Clinical Oncology, 2021, 39, 2791-2802.	0.8	32
36	Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study. BMC Medicine, 2021, 19, 206.	2.3	16

#	Article	IF	Citations
37	Will the clinical development of 4th-generation â€œdouble mutant activeâ€•ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?. Translational Oncology, 2021, 14, 101191.	1.7	24
38	KRAS Inhibitorsâ€“ yes but what next? Direct targeting of KRASâ€“ vaccines, adoptive T cell therapy and beyond. Cancer Treatment Reviews, 2021, 101, 102309.	3.4	37
39	Ensartinib (X-396), an Approved ALK Inhibitor, Falls Out as a Clinically Relevant ROS1 Inhibitor. Journal of Thoracic Oncology, 2021, 16, 1778-1781.	0.5	0
40	Diverse responses to EGFR-TKIs in patients with concurrent germline and somatic EGFR mutations. Lung Cancer, 2021, 162, 207-209.	0.9	1
41	Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer, 2021, 162, 154-161.	0.9	24
42	Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. Clinical Lung Cancer, 2020, 21, 247-254.	1.1	48
43	The Panâ€Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist, 2020, 25, e39-e47.	1.9	13
44	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 2020, 139, 22-27.	0.9	22
45	The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discovery, 2020, 10, 54-71.	7.7	820
46	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. Journal of Thoracic Oncology, 2020, 15, 258-265.	0.5	53
47	ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials. Journal of Thoracic Oncology, 2020, 15, 601-608.	0.5	36
48	Simultaneous RET Solvent-Front and Gatekeeper Resistance Mutations In Trans: A Rare TKI-Specific Therapeutic Challenge?. Journal of Thoracic Oncology, 2020, 15, 479-481.	0.5	4
49	Catalog of 5â€² fusion partners in RET+ NSCLC Circa 2020. JTO Clinical and Research Reports, 2020, 1, 100037.	0.6	17
50	A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC. JTO Clinical and Research Reports, 2020, 1, 100045.	0.6	8
51	Is NRG2Î± Fusion a â€œDoppelgÃngerâ€•to NRG1Î±/Î² Fusions in Oncology?. Journal of Thoracic Oncology, 2020, 15, 878-880.	0.5	4
52	A Catalog of 5â€™ Fusion Partners in ROS1-Positive NSCLC Circa 2020. JTO Clinical and Research Reports, 2020, 1, 100048.	0.6	9
53	A userâ€™s guide to lorlatinib. Critical Reviews in Oncology/Hematology, 2020, 151, 102969.	2.0	26
54	An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitorâ€“Refractory ALK-Positive or ROS1-Positive NSCLC. Journal of Thoracic Oncology, 2020, 15, 1484-1496.	0.5	43

#	Article	IF	Citations
55	Clinical and molecular characteristics of Chinese nonâ€small cell lung cancer patients with ERBB2 transmembrane domain mutations. Molecular Oncology, 2020, 14, 1731-1739.	2.1	5
56	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. Journal of Thoracic Oncology, 2020, 15, 1611-1623.	0.5	43
57	Is Retention of the 5â€² Nononcogenic ALK Fusion Variant a Novel Poor Prognostic Factor in ALK-Positive NSCLC?. Journal of Thoracic Oncology, 2020, 15, 1103-1105.	0.5	2
58	EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer, 2020, 145, 186-194.	0.9	68
59	U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 4785-4794.	3.2	63
60	Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC. Journal of Thoracic Oncology, 2020, 15, e124-e127.	0.5	28
61	Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nature Medicine, 2020, 26, 47-51.	15.2	255
62	KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?. Cancer Treatment Reviews, 2020, 84, 101974.	3.4	143
63	Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases . Lung Cancer: Targets and Therapy, 2020, Volume 11, 13-18.	1.3	6
64	Catalog of 5â€™ Fusion Partners in ALK-positive NSCLC Circa 2020. JTO Clinical and Research Reports, 2020, 1, 100015.	0.6	62
65	How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 2020, 9, 2521-2534.	1.3	15
66	Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1â€“2 trial. Lancet Oncology, The, 2019, 20, 1691-1701.	5.1	233
67	Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer. Trends in Cancer, 2019, 5, 677-692.	3.8	43
68	Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation. JCO Precision Oncology, 2019, 3, 1-6.	1.5	5
69	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. Journal of Thoracic Oncology, 2019, 14, 1794-1806.	0.5	69
70	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer, 2019, 133, 96-102.	0.9	85
71	Neuregulin 1 Fusionâ€“Positive NSCLC. Journal of Thoracic Oncology, 2019, 14, 1354-1359.	0.5	25
72	Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification . Lung Cancer: Targets and Therapy, 2019, Volume 10, 21-26.	1.3	22

#	Article	IF	Citations
73	ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2019, 37, 1370-1379.	0.8	282
74	CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome. Lung Cancer, 2019, 130, 201-207.	0.9	35
75	Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. European Journal of Cancer, 2019, 109, 154-161.	1.3	64
76	Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies . Lung Cancer: Targets and Therapy, 2019, Volume 10, 125-130.	1.3	6
77	Hybrid Captureâ€“Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 255-264.	0.5	53
78	Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Nonâ€“Small-Cell Lung Cancer: Histologic Analysis. Clinical Lung Cancer, 2019, 20, e77-e80.	1.1	9
79	Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).. Journal of Clinical Oncology, 2019, 37, 9011-9011.	0.8	58
80	Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9019-9019.	0.8	13
81	A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.. Journal of Clinical Oncology, 2019, 37, TPS3161-TPS3161.	0.8	30
82	Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discovery, 2018, 8, 836-849.	7.7	298
83	Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis. EBioMedicine, 2018, 29, 112-127.	2.7	63
84	Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. Oncologist, 2018, 23, 776-781.	1.9	8
85	Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. British Journal of Cancer, 2018, 118, 38-42.	2.9	23
86	BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. JCO Precision Oncology, 2018, 2, 1-15.	1.5	24
87	Clinicopathologic Features of Nonâ€“Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precision Oncology, 2018, 2018, 1-12.	1.5	112
88	Liquid Biopsy to Identify Actionable Genomic Alterations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 978-997.	1.8	54
89	Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Nonâ€“Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. Journal of Clinical Oncology, 2018, 36, 2693-2701.	0.8	124
90	Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. Journal of Clinical Oncology, 2018, 36, 1199-1206.	0.8	246

#	Article	IF	Citations
91	EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Nonâ€“Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2018, 2, 1-13.	1.5	8
92	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncology, The, 2018, 19, 1654-1667.	5.1	587
93	Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation. Lung Cancer: Targets and Therapy, 2018, Volume 9, 111-116.	1.3	6
94	Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discovery, 2018, 8, 1529-1539.	7.7	342
95	Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. Journal of Thoracic Oncology, 2018, 13, 1560-1568.	0.5	158
96	STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discovery, 2018, 8, 822-835.	7.7	1,108
97	Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient. Lung Cancer, 2018, 123, 83-86.	0.9	19
98	Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer. ESMO Open, 2018, 3, e000364.	2.0	7
99	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discovery, 2018, 8, 1227-1236.	7.7	321
100	Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-Î± N848â€‰K mutation. Lung Cancer, 2018, 124, 86-89.	0.9	0
101	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. Journal of Thoracic Oncology, 2018, 13, 1530-1538.	0.5	62
102	Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2018, 13, 1312-1323.	0.5	103
103	A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).. Journal of Clinical Oncology, 2018, 36, 2513-2513.	0.8	15
104	Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.. Journal of Clinical Oncology, 2018, 36, 4032-4032.	0.8	4
105	Lorlatinib in patients (Pts) with previously treated ALK⁺ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.. Journal of Clinical Oncology, 2018, 36, 9032-9032.	0.8	13
106	Characterization of 1,233 NSCLCs with non-del19/L858R EGFR mutations (EGFRm) using comprehensive genomic profiling (CGP).. Journal of Clinical Oncology, 2018, 36, 9040-9040.	0.8	3
107	Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.. Journal of Clinical Oncology, 2018, 36, 9062-9062.	0.8	65
108	AXL and CDCP1: A roadmap of innate resistance in EGFR mutant NSCLC.. Journal of Clinical Oncology, 2018, 36, e24003-e24003.	0.8	1

#	Article	IF	Citations
109	Pacific Rim redux: lorlatinib, the ultimate Jaeger?. Annals of Translational Medicine, 2018, 6, S40-S40.	0.7	1
110	An internet-based survey of factors influencing patientsâ€™ satisfaction score and factors leading to discontinuation of treatment in lung cancer patients in China.. Journal of Clinical Oncology, 2018, 36, e18871-e18871.	0.8	0
111	Landscape of kinase rearrangements (kRE) detected in circulating tumor DNA (ctDNA).. Journal of Clinical Oncology, 2018, 36, 12041-12041.	0.8	0
112	Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR -mutated Lung Adenocarcinoma Reveals an Acquired FGFR3 - TACC3 Fusion. Clinical Lung Cancer, 2017, 18, e219-e222.	1.1	15
113	Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers. Oncologist, 2017, 22, 152-157.	1.9	9
114	Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. Oncologist, 2017, 22, 255-263.	1.9	60
115	Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Nonâ€“Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry. Clinical Lung Cancer, 2017, 18, 535-542.	1.1	8
116	MA08.01 A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma. Journal of Thoracic Oncology, 2017, 12, S384-S385.	0.5	6
117	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discovery, 2017, 7, 400-409.	7.7	647
118	Identification of a novel T1151K ALK mutation in a patient with ALK -rearranged NSCLC with prior exposure to crizotinib and ceritinib. Lung Cancer, 2017, 110, 32-34.	0.9	16
119	Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer, 2017, 108, 228-231.	0.9	125
120	P3.02a-016 Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, S1170-S1171.	0.5	0
121	OA08.06 Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical Trials. Journal of Thoracic Oncology, 2017, 12, S273-S274.	0.5	5
122	OA10.01 Comprehensive Genomic Profiling and PDX Modeling of EGFR Exon 20 Insertions: Evidence for Osimertinib Based Dual EGFR Blockade. Journal of Thoracic Oncology, 2017, 12, S279-S280.	0.5	0
123	MA07.01 Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK+ NSCLC. Journal of Thoracic Oncology, 2017, 12, S377.	0.5	0
124	MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S378.	0.5	8
125	MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers. Journal of Thoracic Oncology, 2017, 12, S435-S436.	0.5	1
126	MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S438-S439.	0.5	11

#	Article	IF	Citations
127	P1.02-061 Kinase Fusions in Non-Small Cell Lung Carcinoma Identified by Hybrid Capture Based ctDNA Assay. Journal of Thoracic Oncology, 2017, 12, S524-S525.	0.5	0
128	Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?. Lung Cancer, 2017, 106, 110-114.	0.9	64
129	Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. Journal of Thoracic Oncology, 2017, 12, 932-942.	0.5	129
130	HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. Journal of Thoracic Oncology, 2017, 12, 446-457.	0.5	75
131	Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. Lung Cancer, 2017, 111, 61-64.	0.9	44
132	MET ex14-Positive NSCLC: Time to Take the TherapyÂtoÂthe Target to Aim for a Cure?. Journal of Thoracic Oncology, 2017, 12, 1180-1182.	0.5	0
133	Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1552-1560.	0.5	75
134	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK -positive nonâ€“small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. European Journal of Cancer, 2017, 82, 27-33.	1.3	25
135	Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity. Cardio-Oncology, 2017, 3, .	0.8	14
136	Targeting MET in Lung Cancer: Will Expectations Finally Be MET?. Journal of Thoracic Oncology, 2017, 12, 15-26.	0.5	299
137	Responses to Crizotinib Can Occur in High-Level MET -Amplified Nonâ€“Small Cell Lung Cancer Independent of MET Exon 14 Alterations. Journal of Thoracic Oncology, 2017, 12, 141-144.	0.5	61
138	Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. Journal of Thoracic Oncology, 2017, 12, 137-140.	0.5	102
139	Intracranial Activity of Cabozantinib in MET Exon 14â€“Positive NSCLC with Brain Metastases. Journal of Thoracic Oncology, 2017, 12, 152-156.	0.5	78
140	Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 145-151.	0.5	48
141	The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. Lung Cancer, 2017, 103, 27-37.	0.9	136
142	Alectinib versus Crizotinib in Untreated ALK-Positive Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 829-838.	13.9	1,858
143	Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature. Lung Cancer: Targets and Therapy, 2017, Volume 8, 241-247.	1.3	12
144	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. Journal of Clinical Oncology, 2017, 35, 1403-1410.	0.8	277

#	Article	IF	Citations
145	Further Advances in the Management of Anaplastic Lymphoma Kinaseâ€“Mutated Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2017, 35, 2463-2466.	0.8	7
146	ASCEND-5: too little too late?. Journal of Thoracic Disease, 2017, 9, 3477-3479.	0.6	3
147	Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. Journal of Clinical Oncology, 2017, 35, LBA9008-LBA9008.	0.8	6
148	Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. Journal of Clinical Oncology, 2017, 35, LBA9008-LBA9008.	0.8	16
149	ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer. Translational Lung Cancer Research, 2016, 5, 660-664.	1.3	0
150	High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. Lung Cancer, 2016, 98, 59-61.	0.9	136
151	Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation. Lung Cancer, 2016, 96, 15-18.	0.9	19
152	BRAF V600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAFâ€“MEK Combination Therapy. Cancer Discovery, 2016, 6, 594-600.	7.7	75
153	Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 4079-4085.	0.8	171
154	Missed clinical benefit due to false negatives in testing for EGFR T790M mutations in non-small cell lung cancer. Cancer Treatment and Research Communications, 2016, 9, 131-133.	0.7	1
155	Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. Journal of Thoracic Oncology, 2016, 11, 1493-1502.	0.5	288
156	Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two largeâ€scale multinational trials (<scp>PROFILE</scp> 1005 and 1007). Cancer Medicine, 2016, 5, 617-622.	1.3	46
157	TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling. Lung Cancer, 2016, 97, 48-50.	0.9	36
158	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Oncologist, 2016, 21, 762-770.	1.9	119
159	First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. Journal of Hematology and Oncology, 2016, 9, 23.	6.9	23
160	Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncology, The, 2016, 17, 234-242.	5.1	574
161	Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer. Advances in Experimental Medicine and Biology, 2016, 893, 179-187.	0.8	9
162	Alectinib in Crizotinib-Refractory ALK-Rearranged Nonâ€“Small-Cell Lung Cancer: A Phase II Global Study. Journal of Clinical Oncology, 2016, 34, 661-668.	0.8	548

#	Article	IF	Citations
163	Scientific Advances in Lung Cancer 2015. Journal of Thoracic Oncology, 2016, 11, 613-638.	0.5	231
164	Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations. Journal of Thoracic Oncology, 2016, 11, 281-283.	0.5	1
165	Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. Clinical Cancer Research, 2016, 22, 3281-3285.	3.2	33
166	A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib. Lung Cancer, 2016, 92, 19-21.	0.9	32
167	Identification ofBRAFKinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy. JAMA Oncology, 2016, 2, 272.	3.4	18
168	ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. Lung Cancer, 2016, 91, 70-72.	0.9	46
169	Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 108-108.	0.8	88
170	Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1670-1674.	0.5	197
171	SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM). Journal of Thoracic Oncology, 2015, 10, 387-391.	0.5	67
172	Darkness before dawn, but will the sun always rise?. Cancer, 2015, 121, 2514-2516.	2.0	0
173	Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?. Drug Design, Development and Therapy, 2015, 9, 5641.	2.0	24
174	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget, 2015, 6, 28211-28222.	0.8	57
175	Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. Cancer Discovery, 2015, 5, 850-859.	7.7	632
176	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncology, The, 2015, 16, 830-838.	5.1	786
177	Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient. Lung Cancer, 2015, 87, 207-209.	0.9	21
178	Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Nonâ€“Small-Cell Lung Cancer and Brain Metastases. Journal of Clinical Oncology, 2015, 33, 1881-1888.	0.8	555
179	The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials. Oncologist, 2015, 20, 307-315.	1.9	51
180	Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling. Lung Cancer, 2015, 88, 352-354.	0.9	36

#	Article	IF	Citations
181	Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK -positive NSCLC: Implications for disease assessment and management. Lung Cancer, 2015, 88, 355-359.	0.9	31
182	Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis. Oncologist, 2015, 20, 224-226.	1.9	48
183	Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer, 2015, 89, 357-359.	0.9	82
184	Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies. Oncologist, 2015, 20, 499-507.	1.9	64
185	I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung Cancer, 2015, 88, 231-234.	0.9	68
186	The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Nonâ€“Small-Cell Lung Cancer: A Mini-Review. Clinical Lung Cancer, 2015, 16, 334-339.e1.	1.1	28
187	Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. Oncologist, 2015, 20, 1175-1181.	1.9	26
188	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALKâ€“positive lung cancer. Nature Medicine, 2015, 21, 1038-1047.	15.2	245
189	Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.. Journal of Clinical Oncology, 2015, 33, 3011-3011.	0.8	44
190	A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761).. Journal of Clinical Oncology, 2015, 33, 8019-8019.	0.8	12
191	Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8032-8032.	0.8	97
192	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Oncotarget, 2015, 6, 24320-24332.	0.8	32
193	MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval. Translational Lung Cancer Research, 2015, 4, 820-4.	1.3	13
194	Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS. Chinese Clinical Oncology, 2015, 4, 20.	0.4	14
195	Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning. Translational Lung Cancer Research, 2015, 4, 649-52.	1.3	2
196	Republished: Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?. Postgraduate Medical Journal, 2014, 90, 228-235.	0.9	4
197	Spontaneous Regression of Crizotinib-Associated Complex Renal Cysts During Continuous Crizotinib Treatment. Oncologist, 2014, 19, 1008-1010.	1.9	32
198	Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib. Journal of Thoracic Oncology, 2014, 9, 549-553.	0.5	155

#	Article	IF	Citations
199	ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. Lancet Respiratory Medicine,the, 2014, 2, 966-968.	5.2	14
200	Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-ÃŽÂ±-,) Tj ETQq0 1 0.0 rgBT /Overlock 1	1.0	22
201	Identification of a Novel HIP1-ALK Fusion Variant in Nonâ€“Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib. Journal of Thoracic Oncology, 2014, 9, 1821-1825.	0.5	91
202	Human papilloma virus in non-small cell lung cancer in never smokers: A systematic review of the literature. Lung Cancer, 2014, 83, 8-13.	0.9	44
203	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2014, 15, 1433-1441.	5.1	114
204	Reply to the letter to the editor â€˜Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCâ€™ by Ou et al.. Annals of Oncology, 2014, 25, 2093.	0.6	2
205	Crizotinib in ROS1-Rearranged Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2014, 371, 1963-1971.	13.9	1,656
206	Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncology, The, 2014, 15, 1119-1128.	5.1	631
207	Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and qualityâ€ofâ€life assessments. Cancer, 2014, 120, 2694-2703.	2.0	106
208	To the Editor. Journal of Thoracic Oncology, 2014, 9, e57-e58.	0.5	0
209	Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8001-8001.	0.8	176
210	MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Modern Pathology, 2013, 26, 1632-1641.	2.9	115
211	ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 4273-4281.	3.2	521
212	Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer, 2013, 119, 2383-2390.	2.0	45
213	Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer, 2013, 119, 1627-1635.	2.0	108
214	Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer, 2013, 119, 1969-1975.	2.0	63
215	Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Nonâ€“Small-Cell Lung Cancer?: A Pooled Analysis of the Literature. Journal of Thoracic Oncology, 2013, 8, 1181-1189.	0.5	117
216	The Central Nervous System as a Sanctuary Site in ALK-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1570-1573.	0.5	117

#	Article	IF	Citations
217	Keeping our fingers crossed on 2(nd) generation EGFR TKIs: is better good enough?. Translational Lung Cancer Research, 2013, 2, 55-7.	1.3	0
218	Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification. Discovery Medicine, 2013, 15, 333-41.	0.5	14
219	Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway. Discovery Medicine, 2013, 16, 7-14.	0.5	13
220	Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. Future Oncology, 2012, 8, 451-462.	1.1	48
221	Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1625-1630.	0.5	117
222	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncology, The, 2012, 13, 1011-1019.	5.1	1,176
223	Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology. Oncologist, 2012, 17, 1351-1375.	1.9	206
224	TheEGFRT790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor. Molecular Cancer Therapeutics, 2012, 11, 784-791.	1.9	159
225	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncology, The, 2012, 13, 539-548.	5.1	390
226	ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers. Journal of Clinical Oncology, 2012, 30, 863-870.	0.8	1,435
227	ROS1 as a â€˜druggableâ€™ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. Expert Review of Anticancer Therapy, 2012, 12, 447-456.	1.1	111
228	Chemotherapy is Beneficial for Elderly Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Analysis of Patients Aged 70-74, 75-79, and 80 or Older in Japan. Clinical Lung Cancer, 2012, 13, 442-447.	1.1	8
229	Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence. Critical Reviews in Oncology/Hematology, 2012, 83, 407-421.	2.0	151
230	Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2012, 12, 151-162.	1.1	20
231	Small-Cell Lung Cancer in Never-Smokers: A Case Series With Information on Family History of Cancer and Environmental Tobacco Smoke. Clinical Lung Cancer, 2012, 13, 75-79.	1.1	24
232	SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2012, 30, 7083-7083.	0.8	5
233	Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond. Drug Design, Development and Therapy, 2011, 5, 471.	2.0	165
234	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncology, The, 2011, 12, 1004-1012.	5.1	847

#	Article	IF	Citations
235	Ethnic Differences in Survival Outcome in Patients with Advanced Stage Non-small Cell Lung Cancer: Results of a Meta-Analysis of Randomized Controlled Trials. Journal of Thoracic Oncology, 2011, 6, 1030-1038.	0.5	77
236	Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian in Phase II and III Clinical Trials. Journal of Thoracic Oncology, 2011, 6, 1881-1888.	0.5	48
237	Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Investigational New Drugs, 2011, 29, 352-359.	1.2	27
238	Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification. Journal of Thoracic Oncology, 2011, 6, 942-946.	0.5	407
239	Asymptomatic Profound Sinus Bradycardia (Heart Rate â‰¤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib. Journal of Thoracic Oncology, 2011, 6, 2135-2137.	0.5	51
240	Rare subtypes of adenocarcinoma of the lung. Expert Review of Anticancer Therapy, 2011, 11, 1535-1542.	1.1	16
241	Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 2010, 5, 420-427.	0.5	45
242	Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis of 26,957 Patients with NSCLC. Journal of Thoracic Oncology, 2010, 5, 620-630.	0.5	263
243	Japanese Ethnicity Compared with Caucasian Ethnicity and Never-Smoking Status Are Independent Favorable Prognostic Factors for Overall Survival in Non-small Cell Lung Cancer: A Collaborative Epidemiologic Study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry Databases. Journal of Thoracic Oncology, 2010, 5, 1001-1010.	0.5	125
244	Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era. Journal of Thoracic Oncology, 2010, 5, 1185-1196.	0.5	52
245	Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 2044-2046.	0.5	73
246	A Comparison Study of Clinicopathologic Characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) Patients by Smoking Status. Journal of Thoracic Oncology, 2010, 5, 158-168.	0.5	12
247	Anaplastic Lymphoma Kinase Inhibition in Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2010, 363, 1693-1703.	13.9	4,141
248	The Effect of Tumor Size on Non-Size-Based Descriptors in Staging of Stage I Non-small Cell Lung Cancer: Response. Chest, 2009, 135, 1695-1696.	0.4	1
249	Treatment of Advanced Lung Cancer. Clinical Pulmonary Medicine, 2009, 16, 157-171.	0.3	2
250	Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC): The Importance of Smoking History, Socioeconomic and Marital Statuses, and Ethnicity. Journal of Thoracic Oncology, 2009, 4, 37-43.	0.5	144
251	Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies. Journal of Thoracic Oncology, 2009, 4, 1202-1211.	0.5	75
252	The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition. Journal of Thoracic Oncology, 2009, 4, 300-310.	0.5	66

#	Article	IF	Citations
253	Survival Prognostication in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 785-786.	0.5	2
254	Asian Ethnicity Is a Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer (NSCLC) and Is Independent of Smoking Status. Journal of Thoracic Oncology, 2009, 4, 1083-1093.	0.5	113
255	Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 880-886.	0.5	114
256	Validation Study of the Proposed IASLC Staging Revisions of the T4 and M Non-small Cell Lung Cancer Descriptors Using Data from 23,583 Patients in the California Cancer Registry. Journal of Thoracic Oncology, 2008, 3, 216-227.	0.5	75
257	Prognostic Significance of the Nonâ€“Size-Based AJCC T2 Descriptors. Chest, 2008, 133, 662-669.	0.4	63
258	Capecitabine in Advanced Gastric or Oesophagogastric Cancer. Drugs, 2007, 67, 611-612.	4.9	0
259	Phase II Trial of Sequential Chemotherapy Followed by Chemoradiation, Surgery, and Postoperative Chemotherapy for the Treatment of Stage IIIA/IIIB Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2006, 8, 122-129.	1.1	1
260	Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol. The Cochrane Library, 0, , .	1.5	6